[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582197":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":12,"centralContacts":23,"locations":32,"responsibleParty":68,"collaborators":70,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":12,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":35,"whyStopped":12,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Epicentre","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","NO_INTERVENTION","Children aged 5-36 months will receive R21 via routine EPI vaccination (Year round in Burkina faso, or prior to the malaria season and SMC delivery in Mali)",null,{"label":14,"type":6,"description":15,"interventionNames":16},"Integrated SMC Vaccination","Children aged 3-59 months will receive 3-dose primary series aligned with SMC distribution in an annual campaign",[17],"Other: Annual campaign of the 3-dose primary series vaccine R21\u002FMatrix-M aligned with SMC distribution in children aged 3-59 months",[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":12},"Annual campaign of the 3-dose primary series vaccine R21\u002FMatrix-M aligned with SMC distribution in children aged 3-59 months","in the intenvention arm, the children will get the vaccine R21 Matrix M together with the CPS",[14],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":12,"email":28},"Valérie Briand","CONTACT","+331 40 21 55 55","valerie.briand@epicentre.msf.org",{"name":30,"role":26,"phone":27,"phoneExt":12,"email":31},"Soazic Gardais","soazic.gardais@epicentre.msf.org",[33,52],{"facility":34,"status":35,"city":36,"state":12,"zip":12,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest","RECRUITING","Ouagadougou","Burkina Faso","BF",{"type":40,"coordinates":41},"Point",[42,43],-1.53388,12.36566,{"lat":43,"lon":42},[46,50],{"name":47,"role":26,"phone":48,"phoneExt":12,"email":49},"Natama Hamtandi Magloire","+226 57471950","natamagloire@gmail.com",{"name":47,"role":51,"phone":12,"phoneExt":12,"email":12},"PRINCIPAL_INVESTIGATOR",{"facility":53,"status":35,"city":54,"state":12,"zip":12,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University of Sciences Techniques and Technologies of Bamako","Bamako","Mali","ML",{"type":40,"coordinates":58},[59,60],-7.97522,12.60915,{"lat":60,"lon":59},[63,67],{"name":64,"role":26,"phone":65,"phoneExt":12,"email":66},"Kassoum Kayentao","+223 76460173","kayentao@icermali.org",{"name":64,"role":51,"phone":12,"phoneExt":12,"email":12},{"type":69,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[71,73,76,78],{"name":72,"class":6},"R-Evolution Worldwide",{"name":74,"class":75},"CNRST Burkina Faso","UNKNOWN",{"name":77,"class":75},"USTTB Mali",{"name":79,"class":6},"Liverpool School of Tropical Medicine","100582197","phase-4-integrating-malaria-vaccine-with-seasonal-malaria-chemoprevention-in-west-africa-100582197",false,"NCT06860178","Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa","IMVACS","Inclusion criteria:\n\nControl arms :\n\n* Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination;\n* Resident in the catchment area of a health centre assigned to the control arm;\n* Willingness to comply with the study procedures;\n* Written informed consent from Parent\u002FGuardian.\n\nIntervention arms :\n\n* Children aged 3-59 months at the time of first study vaccination;\n* Resident in the catchment area of a health centre assigned to the intervention arm;\n* Willingness to comply with the study procedures;\n* Written informed consent from Parent\u002FGuardian.\n\nExclusion Criteria:\n\n1. History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines;\n2. Any history of anaphylaxis in relation to vaccination;\n3. Known chronic illness;\n4. Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial;\n5. History of vaccination with another malaria vaccine. -",true,"ALL","3 Months","59 Months",{"count":92,"type":93},40000,"ESTIMATED","INTERVENTIONAL",[96],"PHASE4","This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21 malaria vaccine alongside SMC among children in areas with highly seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a health centre. Clusters will be randomised to receive either year-round age-based routine EPI vaccination for children aged 5-36 months (\"Routine EPI Vaccination\") in Burkina Faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and SMC delivery (''Routine Pre-SMC vaccination'') in Mali versus an annual campaign of the 3-dose primary series aligned with SMC distribution in children aged 3-59 months (\"Integrated SMC Vaccination\") in each country. Effectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-effectiveness.\n\nMalaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. Cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. In addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of R21\u002FMatrix-M will be assessed.",[99],"Malaria Vaccine",[101,102,103,104,105],"malaria","CPS","pediatric","vaccine","R21","2025-08-05",{"date":108,"type":109},"2025-08-08","ACTUAL",{"date":111,"type":109},"2025-06-10",{"date":113,"type":93},"2027-12",{"name":5,"class":6},2]